@article{LCBL44398,
author = {凯 郭 和 宏威 凌},
title = {沙格列汀联合二甲双胍治疗2型糖尿病合并脑梗死的临床疗效},
journal = {临床与病理杂志},
volume = {42},
number = {2},
year = {2021},
keywords = {},
abstract = {目的:观察沙格列汀联合二甲双胍治疗2型糖尿病(type 2 diabetes mellitus,T2DM)合并脑梗死的临床疗效。方法:选择2018年9月至2020年6月于徐州医科大学附属医院内分泌科住院的T2DM合并脑梗死的患者139例,将上述患者随机分为2组,A组接受沙格列汀联合二甲双胍治疗,B组接受格列美脲片治疗。2组患者连续治疗12周,比较治疗前后血糖、中性粒细胞计数与淋巴细胞计数的比值(neutrophil-to-lymphocyte ratio,NLR)、血小板计数与淋巴细胞计数的比值(platelet-to-lymphocyte ratio,PLR)、血糖波动指标、颈动脉内膜中层厚度(carotid intima-media thickness,CIMT)。结果:治疗12周后,2组空腹血糖(fasting blood glucose,FBG)、餐后2 h血糖(2-h postprandial blood glucose,2hPG)、糖化血红蛋白(glycosylated hemoglobin A1c,HbA1c)均较治疗前明显降低(P},
url = {https://lcbl.amegroups.com/article/view/44398}
}